FORT MYERS, Fla., Feb. 26, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at the global ASCO® 2026 ...
Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib). Background: The majority of non- prostate ...
TAMPA, Fla. — Patient-reported outcomes are important indicators of how cancer drugs impact patients’ lives. By assessing the benefits and risks of drugs from a patient’s perspective, scientists and ...
Dr. Maluf emphasized that his discussion would focus on penile squamous cell carcinoma and genitourinary basket trials. At ASCO 2024, Dr. Maluf presented the HERCULES (LACOG 0218), a phase II trial of ...
Palliative care (PC) plays a critical role in managing the difficulties associated with genitourinary malignancies. Its primary aim is to improve the overall health of patients, provide support to ...
PROEAS graph reporting the different PROEAS scores per category for randomized clinical trials individualized by GU tumor type. Abbreviations: PROEAS: Patient Reported Outcome Endpoint Analysis Score; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results